WebDyne Therapeutics Inc 's competitive profile, comparisons of quarterly results to its competitors, by sales, income, profitability, market share by products and services - … WebDyne Therapeutics Inc Working Capital Per Revenue on the trailing twelve month basis from the forth quarter 2024 to forth quarter 2024, Trends and Ranking, Fundamental Ratios - CSIMarket ... Dyne Therapeutics Inc 's Competition Performance; Dyne Therapeutics Inc 's Competitors Results; DYN's Competitors Stock Performance;

Dyne Therapeutics Company Profile Management and Employees …

WebDyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for … WebDyne Therapeutics has 5 employees at their 1 location and $165 m in total funding,. See insights on Dyne Therapeutics including office locations, competitors, revenue, … grace church galena

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In …

WebApr 3, 2024 · “ Dyne’s breakthrough approach brings the power of modern oligo therapeutics and other payloads to patients with serious muscle diseases," said Jason Rhodes, a partner at Atlas Venture and ... WebMay 16, 2024 · DYNE-101 is designed to enable targeted delivery to muscle tissue and address the genetic basis of the disease. The new data being presented during ASGCT evaluated monthly repeat doses of DYNE-101 ... WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … grace church gisborne